Chelsea Salyer, MD
Gynecologic Oncology · Richmond, VANPI 1265826135
Payments from drug & device makers
What this record shows
This record is dominated by education: $1,266 of the $2,031 with a category attached, or 62.3%. 8 manufacturers reported payments, led by Intuitive Surgical at 56.9% of the total. Reporting peaked in 2022 at $1,058 and has fallen 90.9% since, to $97 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in VA, where the typical reported total is $1,719.
Across 13 payments — averaging $156.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- AstraZeneca$245
- Medical Device Business Services, Inc.$137
- GSK$129
- Eisai Inc.$125
- Myriad Genetic Laboratories, Inc.$114
- plus $125 from 2 others
Across 7 payments — averaging $55,923 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$355K
- Regeneron$36K
What the payments were for
- Food & beverage$76538%
- Education$1,26662%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $1,156 |
| AstraZeneca | 2 | $245 |
| Medical Device Business Services, Inc. | 1 | $137 |
| GSK | 2 | $129 |
| Eisai Inc. | 1 | $125 |
| Myriad Genetic Laboratories, Inc. | 1 | $114 |
| Caris MPI, Inc. | 1 | $97 |
| Merck | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$1,000
- LYNPARZA$245
- STRATAFIX$137
- LENVIMA$125
- myRisk$114
How this compares
$2,031 in reported general payments places this provider in the 50th percentile of 47 gynecologic oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 13 | $217 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Richmond
- Cecelia BoardmanRichmond$577K
- Randal WestRichmond$8K
- Tyler FordRichmond$6K
- Johnny HydeRichmond$6K
- Sarah TemkinRichmond$2K
- Richard BoothbyRichmond$495
- Paola GehrigRichmond$209
- John NashRichmond$125
- Charles JonesRichmond$15
- Leslie RandallFairfax$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.